Original ArticlesTransplantation

Dialysis Facility Profit Status and Early Steps in Kidney Transplantation in the Southeastern United States

Laura J. McPherson, Elizabeth R. Walker, Yi-Ting Hana Lee, Jennifer C. Gander, Zhensheng Wang, Amber M. Reeves-Daniel, Teri Browne, Matthew J. Ellis, Ana P. Rossi, Stephen O. Pastan, Rachel E. Patzer and on behalf of the Southeastern Kidney Transplant Coalition
CJASN June 2021, 16 (6) 926-936; DOI: https://doi.org/10.2215/CJN.17691120

Abstract

Background and objectives Dialysis facilities in the United States play a key role in access to kidney transplantation. Previous studies reported that patients treated at for-profit facilities are less likely to be waitlisted and receive a transplant, but their effect on early steps in the transplant process is unknown. The study’s objective was to determine the association between dialysis facility profit status and critical steps in the transplantation process in Georgia, North Carolina, and South Carolina.

Design, setting, participants, & measurements In this retrospective cohort study, we linked referral and evaluation data from all nine transplant centers in the Southeast with United States Renal Data System surveillance data. The cohort study included 33,651 patients with kidney failure initiating dialysis from January 1, 2012 to August 31, 2016. Patients were censored for event (date of referral, evaluation, or waitlisting), death, or end of study (August 31, 2017 for referral and March 1, 2018 for evaluation and waitlisting). The primary exposure was dialysis facility profit status: for profit versus nonprofit. The primary outcome was referral for evaluation at a transplant center after dialysis initiation. Secondary outcomes were start of evaluation at a transplant center after referral and waitlisting.

Results Of the 33,651 patients with incident kidney failure, most received dialysis treatment at a for-profit facility (85%). For-profit (versus nonprofit) facilities had a lower cumulative incidence difference for referral within 1 year of dialysis (−4.5%; 95% confidence interval, −6.0% to −3.2%). In adjusted analyses, for-profit versus nonprofit facilities had lower referral (hazard ratio, 0.84; 95% confidence interval, 0.80 to 0.88). Start of evaluation within 6 months of referral (−1.0%; 95% confidence interval, −3.1% to 1.3%) and waitlisting within 6 months of evaluation (1.0%; 95% confidence interval, −1.2 to 3.3) did not meaningfully differ between groups.

Conclusions Findings suggest lower access to referral among patients dialyzing in for-profit facilities in the Southeast United States, but no difference in starting the evaluation and waitlisting by facility profit status.

Introduction

Total and permanent kidney failure affects >700,000 adults in the United States (1). Kidney transplantation improves patient survival and quality of life compared with dialysis and reduces total cost of care (2 ⇓–4). Despite the demonstrated long-term benefits of transplantation over dialysis, <15% of all patients with kidney failure have completed the necessary steps to be waitlisted for a kidney transplant (5). To determine why the majority of patients with kidney failure are not waitlisted, earlier steps in the kidney transplantation process, including referral to a kidney transplant center to undergo a medical and psychosocial evaluation, must be studied.

Nearly 90% of patients with incident kidney failure receive treatment in a dialysis facility (1). National guidelines from the Organ Procurement and Transplantation Network require education about transplantation as a treatment option within 90 days of kidney failure start and recommend referring patients for evaluation if a clinician is uncertain of transplant eligibility (4). Several studies have shown that patients treated in for-profit facilities have lower rates of waitlisting and kidney transplantation (6 ⇓ ⇓ ⇓–10). However, the effect of for-profit status on steps prior to waitlisting remains unknown because national surveillance databases do not routinely collect these data (6,7).

The purpose of this study was to examine the association between dialysis facility profit status, referral from a dialysis facility to a transplant center, and start of evaluation at the transplant center. We focused on Georgia, North Carolina, and South Carolina (ESRD Network 6), a region with the highest burden of kidney failure in the country but also the lowest standardized transplantation rates (11), where an existing early transplant access registry documents these critical first steps to transplant.

Materials and Methods

Data Source

Patient-level clinical and demographic data were obtained from the United States Renal Data System (USRDS) database, a publicly available national database that includes information on almost all of the patients with kidney failure in the United States. USRDS collects data at the patient’s initiation of dialysis using the Centers for Medicare & Medicaid Services (CMS) CMS-2728 form (1).

Dialysis facility–level data were obtained from Dialysis Facility Compare (DFC; 2016) and Dialysis Facility Report (DFR; 2013–2016). DFC reports information on dialysis facility profit status and corporate ownership (12). DFR captures information on facility-level patient characteristics, mortality, treatment patterns, and transplantation rates (13). Dialysis facility–level data from DFC and DFR were linked to patient-level USRDS data using the dialysis facility’s CMS certification number. Neighborhood factors by zip code were determined using the 2010–2014 American Community Survey.

Patient-level referral and start of evaluation data were collected from all transplant centers in Georgia, North Carolina, and South Carolina and linked to USRDS data as previously described (14). This study was approved by the institutional review board at Emory University (IRB00079596).

Study Population

All patients with incident kidney failure registered within USRDS in Georgia, North Carolina, and South Carolina who initiated dialysis between January 1, 2012 and August 31, 2016 were considered for inclusion, and a match merge was made with the Early Transplant Access Registry data of first referrals. There were 40,453 patients with incident kidney failure from 782 facilities eligible for merging. A total of 6252 patients were excluded for preemptive referral (n=5276), preemptive evaluation (n=2966), preemptive waitlisting (n=1548), receiving care in a Veterans Affairs–affiliated facility (n=385), receiving care in a transplant center–based facility (n=59), receiving care in a facility with fewer than ten patients (n=1056), missing profit status (n=5), and missing patient-level information (n=546), leaving 33,651 patients in the final study population (Figure 1). Exclusions on the basis of preemptive referral, evaluation, and waitlisting were defined as having a date of completion for each step prior to the date of dialysis start.

Figure 1.
Figure 1.

Data merge and cohort selection to examine the relationship between dialysis facility profit status and access to kidney transplantation. GA, Georgia; ID, identification; NC, North Carolina; SC, South Carolina; USRDS, United States Renal Data System; VA, Veterans Affairs.

Outcomes and Study Variables

The primary exposure was dialysis facility profit status, defined as for profit or nonprofit within the USRDS database. The primary outcome was incident referral for transplant evaluation at a transplant center. Referral to a transplant center was defined as receipt of the referral form at a transplant center. Patients were censored for referral date, death, or end of study period (August 31, 2017 for referral). In the event that a patient was referred more than once during the study period, the patient’s first referral following dialysis initiation was used as the referral date. Secondary outcomes included start of transplant evaluation at a transplant center (among referred patients), defined as the first visit to a transplant center, satellite clinic, or required education class; waitlisting for transplant (among evaluated patients) was defined as placement on the deceased donor kidney transplantation waiting list. For evaluation and waitlisting, patients were followed from referral to date of evaluation/waitlisting, death, or end of study period (March 1, 2018), whichever occurred first. Patients with negative follow-up time from referral to evaluation and/or evaluation to waitlisting were assigned a follow-up time of 1 day for evaluation and waitlisting.

Patient-level demographic, clinical, and socioeconomic characteristics were obtained from USRDS at the time of dialysis initiation. Demographics included age, sex, race/ethnicity, and attributed cause of kidney failure. Clinical characteristics included comorbidities (body mass index [BMI] ≥35 kg/m2, atherosclerotic heart disease, other cardiac disease, cerebrovascular disease, peripheral vascular disease, hypertension, diabetes, chronic obstructive pulmonary disease, tobacco use, and active malignancy), receipt of nephrology care prior to dialysis initiation, and education on transplant as a treatment option (versus not informed due to medical reasons). Patient insurance provider (Medicare, Medicaid, employer coverage, other coverage, or no coverage) was examined as a patient-level socioeconomic factor.

At the neighborhood zip code level, socioeconomic indicators included the percentage of residents living below the poverty line, percentage of Black residents, and percentage of residents with a high school degree. Dialysis facility–level characteristics included facility size and patient-social worker ratio.

Statistical Analyses

A small number of patients (546 patients; 2%) had incomplete CMS-2728 forms; therefore, we conducted a complete patient analysis (15). The cumulative incidence function estimated the probabilities of referral at 6, 12, 24, and 36 months from the initiation of dialysis; evaluation at 6, 12, and 24 months from referral date; and waitlisting at 6 and 12 months from evaluation date (due to limited follow-up on waitlisting) with death treated as a competing risk. The 95% confidence intervals (95% CIs) were calculated with variance estimates. Bootstrapping was used to perform 1000 resamples of the event with replacement to accurately compute the 95% CIs for cumulative incidence differences.

Cause-specific Cox models were used to assess characteristics associated with each outcome. For the main analysis, time to each event (referral, evaluation start, or waitlisting censored for end of study period) was calculated using cause-specific hazard ratios (HRs) and 95% CIs, with death treated as a competing risk. Covariates with known associations between profit status and/or access to transplantation were included in the multivariable models. Robust sandwich variance estimators were used to account for potential clustering within dialysis facilities. The proportional hazard assumption was tested for all outcomes.

As in our prior work, patients who were referred, evaluated, waitlisted, or transplanted prior to starting dialysis were excluded in main analyses because the events occurred prior to the follow-up period. However, because dialysis facilities still have the opportunity to facilitate patients’ access in early steps of transplant, in a sensitivity analysis, we included patients who were preemptively referred and assigned them a follow-up time of 1 day from dialysis initiation for analyses examining referral and 1 day from referral for analyses examining evaluation start and waitlisting.

SAS version 9.4 (SAS Institute, Cary, NC) and R (version 3.6.3) were used for cohort development, data management, and statistical analysis. Two-sided P values were used for all analyses, and P=0.05 was considered statistically significant.

Results

Baseline Characteristics

We included 33,651 patients with incident kidney failure from Georgia, South Carolina, and North Carolina. Among included patients, most received dialysis care at a for-profit facility (85%) compared with a nonprofit facility (15%). In the overall population, the mean age was 60 years (SD: 13 years), 55% were men, and 56% were non-Hispanic Black patients (Table 1).

View this table:
Table 1.

Characteristics of patients with incident kidney failure initiating dialysis between January 1, 2012 and August 31, 2016 in Georgia, North Carolina, and South Carolina followed through March 1, 2018: Overall and stratified by dialysis facility profit status

There were no significant differences in age, sex, or race/ethnicity between patients at for-profit versus nonprofit facilities. Compared with patients treated in for-profit facilities, patients treated in nonprofit facilities had significantly higher proportions of all 11 assessed comorbidities with the exception of BMI. Differences were observed in attributable cause of kidney failure, with more kidney failure cases attributed to hypertension in for-profit facilities compared with nonprofit facilities (38% versus 33%, respectively). Patients treated in for-profit facilities were more likely to have employer-based insurance (18% versus 15%, respectively) or Medicaid (25% versus 24%, respectively), whereas patients in nonprofit facilities were more likely to lack coverage at kidney failure start (12% versus 10%, respectively) (Table 1).

Of note, among patients excluded, patients referred prior to dialysis start were more likely to be younger, have received nephrology care, have employer insurance, and live in a neighborhood with <20% of residents living below the poverty line compared with the study population; they were also less likely to have nine of the 11 comorbidities compared with patients in the main analysis (Supplemental Table 1).

Referral for Transplantation Evaluation following Initiation of Dialysis

A total of 44% of patients (n=14,729) were referred for transplant during the 4-year study period, including 43% in for-profit dialysis facilities versus 47% in nonprofit dialysis facilities (P<0.001) (Supplemental Table 2). Among those referred, the median time from dialysis initiation to referral was 4.4 months (interquartile range [IQR], 2.1–10.3), with a longer median time to referral for patients treated at for-profit facilities (4.6 months; IQR, 2.1–10.5 months) versus nonprofit facilities (3.8 months; IQR, 2.0–9.1 months; P<0.001).

A total of 11,272 patients died during the follow-up period, including similar proportions of patients in for-profit (34%) and nonprofit (33%) facilities. In cumulative incidence analysis with death treated as a competing risk, patients treated in for-profit facilities had lower cumulative incidence of referral at 6 months and 1 year compared with patients treated in nonprofit facilities (cumulative incidence difference, −5.1%; 95% CI, −6.5% to −3.8% and −4.5%; 95% CI, −6.0% to −3.2%, respectively). The lower incidence of referral among patients treated in for-profit versus nonprofit facilities remained consistent over time (Figure 2A).

Figure 2.
Figure 2.
Figure 2.

Patients receiving dialysis at for-profit (versus nonprofit) facilities had a lower cumulative incidence difference for referral within 1 year of dialysis. There was no meaningful difference between cumulative incidence of starting the evaluation within 6 months of referral (among referred patients) and being waitlisted within 6 months of evaluation (among evaluated patients) by dialysis facility profit status. (A) Cumulative incidence and cumulative incidence difference of referral for kidney transplantation by profit status among patients with incident kidney failure between January 1, 2012 and December 31, 2016. (B) Cumulative incidence and cumulative incidence difference of starting evaluation at a transplant center among patients with incident kidney failure between January 1, 2012 and December 31, 2016 who were referred. No significant cumulative incidence differences were observed between patients at for-profit versus nonprofit facilities in starting evaluation at 6, 12, and 24 months after being referred. (C) Cumulative incidence and cumulative incidence difference of waitlisting among patients with incident kidney failure between January 1, 2012 and December 31, 2016 who were evaluated at a transplant center. *The cumulative incidence difference between for-profit and nonprofit facilities was significant. aCumulative incidence was calculated using cumulative incidence function and adjusted for competing risk of death (logrank <0.001); b95% CIs for cumulative incidence difference were estimated by bootstrap method. 95% CIs, 95% confidence intervals.

In the unadjusted cause-specific Cox model, patients treated at for-profit facilities were less likely to receive a referral for transplant evaluation (HR, 0.87; 95% CI, 0.78 to 0.97). In multivariable analysis, after adjusting for age, sex, race/ethnicity, primary cause of kidney failure, the presence of selected comorbidities, facility size, pre-/post-Kidney Allocation System era, insurance status, and not informed of transplant options due to medical reasons, patients treated at a for-profit facility were less likely to receive a referral compared with patients treated at a nonprofit facility (HR, 0.84; 95% CI, 0.76 to 0.93) (Table 2).

View this table:
Table 2.

Crude and adjusted cause-specific hazard ratios between dialysis facility profit status and referral for kidney transplantation during follow-up among patients with incident kidney failure who initiated dialysis in dialysis facilities in Georgia, North Carolina, and South Carolina (nonprofit facilities: n=5059 patients; for-profit facilities: n=28,592)

View this table:
Table 3.

Crude and adjusted cause-specific hazard ratios between dialysis facility profit status and evaluation for kidney transplantation during follow-up among referred patients with incident kidney failure who initiated dialysis in dialysis facilities in Georgia, North Carolina, and South Carolina (nonprofit facilities: n=5059 patients; for-profit facilities: n=28,592)

View this table:
Table 4.

Crude and adjusted cause-specific hazard ratios between dialysis facility profit status and waitlisting for kidney transplantation during follow-up among evaluated patients with incident kidney failure who initiated dialysis in dialysis facilities in Georgia, North Carolina, and South Carolina (nonprofit facilities: n=5059 patients; for-profit facilities: n=28,592)

Profit Status and Evaluation Start at a Transplant Center

Among patients referred for evaluation at a transplant center, 53% started evaluation (23% of all patients with kidney failure), and among those who were evaluated, the median follow-up time was 2.3 months (IQR, 1.5–3.6) from referral to evaluation. Of total referred, 38% started the evaluation within 6 months of the referral (n=5605) (Figure 1). Of the 12,343 patients referred for transplant from for-profit facilities, 53% started the evaluation versus 55% of the 2386 patients referred from nonprofit facilities (Supplemental Table 2). The median times from referral to evaluation were similar between for-profit facilities (2.3 months; IQR, 1.4–3.6 months) versus nonprofit facilities (2.4 months; IQR, 1.5–3.6 months; P=0.18).

Patients referred from for-profit facilities had similar 6-month cumulative incidence of starting evaluation compared with patients in nonprofit facilities (cumulative incidence difference, −1.0%; 95% CI, −3.1% to 1.3%). Trends remained consistent at 1 and 2 years (cumulative incidence differences, −1.4%; 95% CI, −3.5% to 0.8% and −1.9%; 95% CI, −4.1% to 0.3%, respectively) (Figure 2B).

In the unadjusted cause-specific Cox model, there was no difference in evaluation start among patients referred between for-profit and nonprofit groups (HR, 0.95; 95% CI, 0.85 to 1.06), and results were consistent after adjustment for various demographic, clinical, and socioeconomic factors (HR, 0.92; 95% CI, 0.83 to 1.03) (Table 3).

Profit Status and Placement on the Deceased Donor Waitlist for Transplant

Among patients evaluated at a transplant center, 37% were waitlisted (9% of all evaluated patients). Among those who were waitlisted, the median time from evaluation to waitlisting was 5.3 months (IQR, 3.1–9.4). Of the 7815 patients evaluated for transplant, 1307 (55%) and 6508 (53%) were from nonprofit and for-profit facilities, respectively. Among those evaluated at a nonprofit facility, 454 (35%) were waitlisted. Similarly, among those evaluated at a for-profit facility, 2426 (37%) were waitlisted (Supplemental Table 2). There was no difference in median time from evaluation to waitlisting between for-profit facilities (5.3 months; IQR, 3.1–9.4 months) and nonprofit facilities (5.5 months; IQR, 3.3–9.6 months; P=0.44). Patients dialyzing at for-profit facilities had similar 6-month cumulative incidence of being waitlisted compared with patients in nonprofit facilities (cumulative incidence differences, 1.0; 95% CI, −1.2% to 3.3%) (Figure 2C).

In the unadjusted cause-specific Cox model, there was no significant difference in waitlisting among patients evaluated for transplant between for-profit and nonprofit groups (HR, 1.11; 95% CI, 0.96 to 1.28), and results were attenuated after adjustment for selected demographic, clinical, and socioeconomic factors (HR, 1.05; 95% CI, 0.92 to 1.19) (Table 4).

In a sensitivity analysis including patients who were preemptively referred, before they started dialysis, we found that our results were slightly attenuated for the outcome of referral (HR, 0.87; 95% CI, 0.79 to 0.97), and among patients referred, there was a small (approximately 12%) difference in evaluation start among those referred between patients treated at for-profit versus nonprofit facilities in the adjusted model (HR, 0.88; 95% CI, 0.79 to 0.98). Similar to main results, there was no difference in waitlisting by profit status (HR, 1.03; 95% CI, 0.91 to 1.17) (Supplemental Table 3).

Although the goal of this manuscript was to examine the overall effect of dialysis facility profit status on early transplant access, in a post hoc analysis, we did test for interaction effects between patient age and profit status in the referral model to better contextualize our findings (Supplemental Table 4). We found that patients ≥65 years (less likely to be medically eligible for transplant due to older age) are less likely to be referred in for-profit facilities compared with nonprofit facilities. However, this finding should be interpreted with caution as the power to detect an interaction effect may be limited by study size.

Discussion

Among adult patients with kidney failure treated in dialysis facilities within Georgia, North Carolina, and South Carolina, patients in for-profit dialysis facilities had lower referral for transplant compared with patients in nonprofit dialysis facilities. However, in this population in the Southeast, after patients were referred from a dialysis facility, there were no significant differences in the start of the transplant evaluation or waitlisting by profit status. To our knowledge, this was the first study to examine the relationship between dialysis facility profit status and early steps in the transplantation process in a multistate region.

There are several explanations for our findings. First, it is possible that for-profit facilities are under-referring some patients who could be good candidates for transplant. Patients’ health status can delay the process of accessing transplant, as evidenced by increased comorbidities associated with decreased odds of waitlisting (16). We found that although patients treated in for-profit facilities were less likely to have comorbidities that may limit their medical eligibility for transplant at the initiation of dialysis, they were less likely to receive a referral at all time points compared with patients treated in a nonprofit facility. Another explanation for these findings is that for-profit dialysis facilities are more selective in identifying patients more likely eligible for transplantation and that unmeasured comorbidities that influence medical eligibility could explain the lower referral among for profit dialysis facilities. However, unmeasured comorbidities may differentially affect referral practices and potentially result in unmeasured confounding.

Patient education about all treatment options, a CMS mandate, is crucial for patients with kidney failure to access transplant (8,17). In our study, we found no difference in the proportion of patients educated about transplant as a treatment option by facility profit status. However, little is known about the quality of education that patients receive, and prior reports have reported discrepancies in this measure (18,19). From a financial perspective, patient education has limited reimbursement, which may lead to practices spending minimal time on increasing patient knowledge of transplantation (8).

It is unclear who identifies patients for referrals at dialysis facilities, whether the education and referral process differ by profit status, reasons for nonreferral, differences in patient interest, and how smaller for-profit dialysis facilities may differ from larger ones. Although further research is needed to determine why for-profit dialysis facilities refer fewer patients, our findings suggest that targeted interventions and policies may be needed to incentivize transplant access. This strikingly wide variation in dialysis referral rates in Georgia, North Carolina, and South Carolina—ranging from 0% to 100% (14)—coupled with our findings of lower referral at for-profit facilities further indicates a need for consistent guidelines on referral. The new CMS Percent of Prevalent Patients Waitlisted proposal seeks to encourage dialysis facilities to increase the proportion of prevalent patients waitlisted (20). However, dialysis facilities have little control over who is listed for transplant and who is deemed ineligible, although they may have influence over encouraging referred patients to start or complete the evaluation process. In this study, we found no differences in evaluation start rates among referred patients and no differences in waitlisting rates among patients who started the evaluation across for-profit versus nonprofit dialysis facilities, but we did find substantial attrition across transplant steps. This suggests that dialysis facilities may have the most opportunity to intervene by increasing equitable referrals for transplant. Although the waitlisting metric may have some effect on some facilities, the results of this study highlight the need to improve patient access to transplantation prior to waitlisting. Quality metrics focused on transplant referrals have been developed for both dialysis facilities (21) and transplant centers (22), but national data on referral are needed to implement these quality metrics to ensure equitability in transplant access.

Our work extends recent analyses showing substantial variation in referral and evaluation start across southeastern dialysis facilities and the barriers and facilitators associated with early transplant access (14). Although it is difficult to assess who should be referred, and we do not have data on the reasons patients may not be a candidate, these rates of referral are likely too low. In recent years, several policies have incentivized increased access to transplantation. CMS initiated a targeted goal to increase the number of waitlisted patients with kidney failure to 30% by 2023 (23), and the July 2019 Advancing American Kidney Health Initiative Executive Order aims to double the number of kidney transplants by 2030 in part through new payment models to financially reward nephrologists and dialysis facilities for transplants (24). It is expected that the mandatory CMS ESRD Treatment Choices model, which started in January 2021 and incentivizes waitlisting through a modality performance score, may lead to increased referrals for transplantation (25). Future research should study how these policies may differentially affect transplant access by profit status.

This study has several limitations. First, this study was limited to Georgia, North Carolina, and South Carolina, and outcome data occurring outside of this region are not captured; results may not be generalizable outside of the Southeast. Our findings demonstrate the need for national surveillance data collection on early transplant steps to better understand and address barriers in transplant access.

Second, this study is limited to patients with kidney failure who require dialysis. Patients with CKD were not included, so selection bias is possible. However, in a sensitivity analysis including patients who were referred prior to starting dialysis, we did not find a meaningful difference from our main findings in referral, evaluation start, or waitlisting by profit status.

Third, we have limited follow-up time to examine waitlisting. Although follow-up time is equivalent across profit status to reflect accurate relative rates, absolute event rates for waitlisting are lower than national rates because of limited follow-up time, resulting in wide 95% CIs. Further follow-up may be needed to confirm null associations with respect to waitlisting by profit status.

Finally, transplant centers differ in their criteria for transplant eligibility, and variation in these criteria may affect dialysis facility’s choice to refer. Aside from common contraindications for transplant (e.g., high BMI, heart failure, tobacco use, or cancer diagnosis), our dataset is limited in that it lacks information on reasons for patient nonreferrals (such as other medical factors or patient interest), which could differentially affect referral practices by profit status and lead to unmeasured confounding. As our data-sharing agreement removed the transplant center identifiers, differences in individual transplant center criteria for eligibility were not assessed. Among US patients with kidney failure in the Southeast United States, for-profit facility status was associated with lower referral, but not lower evaluation rates or waitlisting, compared with nonprofit facility status. This study emphasizes the importance of studying earlier steps prior to waitlisting to understand and address barriers to transplantation. Further research is needed to understand the mechanisms behind the association and to determine interventions that may reduce this disparity.

Disclosures

T. Browne reports employment with the University of South Carolina and serving as a scientific advisor or member of ESRD Network 6. M.J. Ellis reports employment with Duke University Medical Center; consultancy agreements with Alexion, Bristol Myers Squibb, Genzyme Sanofi, RadMD, Relypsa, and Veloxis; receiving honoraria from Bristol Myers Squibb, MedIQ, RadMD, Relypsa, and Veloxis; serving as a scientific advisor or membership with American Journal of Transplantation; and speakers bureau for Bristol Myers Squibb, Genzyme Sanofi, and Relypsa. J.C. Gander reports employment with Kaiser Permanente. L.J. McPherson reports employment with Laney Graduate School. S.O. Pastan reports employment with Emory University School of Medicine; serving as a scientific advisor or member of the board of directors of ESRD Network 6, the board of directors of the National Forum of Networks, and the board of directors and the scientific advisory board of the National Kidney Foundation; and serving as an associate editor of Kidney International Reports. R.E. Patzer reports employment with Emory University School of Medicine and serving on the American Journal of Transplantation editorial board, on the CJASN editorial board, and as chair of the United Network for Organ Sharing Data Advisory Board. R.E. Patzer’s spouse has ownership interest in Vital Software. E.R. Walker reports employment with the Medical University of South Carolina. All remaining authors have nothing to disclose.

Funding

This work was supported in part by National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK122701 and National Institutes of Health, National Center for Advancing Translational Sciences awards UL1TR002378 and TL1TR002382.

Acknowledgments

The data reported here have been supplied by USRDS. The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the US Government. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Supplemental Material

This article contains the following supplemental material online at http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.17691120/-/DCSupplemental.

Supplemental Table 1. Sensitivity analysis of the characteristics of patients with incident ESKD initiating dialysis between January 1, 2012 and August 31, 2016 in Georgia, North Carolina, and South Carolina followed through March 1, 2018; the study population was compared with preemptively referred patients.

Supplemental Table 2. Characteristics and bivariable cause-specific hazard ratios of patients with incident ESKD kidney failure who initiated dialysis between January 1, 2012 and August 31, 2016 in Georgia, North Carolina, and South Carolina who were referred for transplant, who initiated evaluation at a transplant center, and who were waitlisted during follow-up (to August 31, 2017 for referral and to March 1, 2018 for evaluation and waitlisting).

Supplemental Table 3. Sensitivity analysis results of the crude and adjusted cause-specific hazard ratios between dialysis facility profit status and referral, evaluation, and waitlisting for kidney transplantation during follow-up among patients with incident ESKD who initiated dialysis in dialysis facilities in Georgia, North Carolina, and South Carolina.

Supplemental Table 4. Sensitivity analysis results of adjusted cause-specific hazard ratios between dialysis facility profit status and referral for kidney transplantation during follow-up among patients with incident kidney failure who initiated dialysis in dialysis facilities in Georgia, North Carolina, and South Carolina, examining the interaction effect between age and profit status.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • See related editorial, “Dialysis and Transplant Access: Kidney Capitalism at a Crossroads?,” on pages 846–847.

  • Received November 11, 2020.
  • Accepted March 22, 2021.

References

  1. ↵
    1. United States Renal Data System
    : United States Renal Data System, 2018 Annual Data Report: An Overview of the Epidemiology of Kidney Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2018. Available at: https://www.usrds.org/
  2. ↵
    1. Tonelli M,
    2. Wiebe N,
    3. Knoll G,
    4. Bello A,
    5. Browne S,
    6. Jadhav D,
    7. Klarenbach S,
    8. Gill J
    : Systematic review: Kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 11: 2093–2109, 2011 doi:10.1111/j.1600-6143.2011.03686.x 21883901
    OpenUrlCrossRefPubMed
  3. ↵
    1. Vanholder R,
    2. Annemans L,
    3. Brown E,
    4. Gansevoort R,
    5. Gout-Zwart JJ,
    6. Lameire N,
    7. Morton RL,
    8. Oberbauer R,
    9. Postma MJ,
    10. Tonelli M,
    11. Biesen WV,
    12. Zoccali C; European Kidney Health Alliance
    : Reducing the costs of chronic kidney disease while delivering quality health care: A call to action. Nat Rev Nephrol 13: 393–409, 2017 doi:10.1038/nrneph.2017.63 pmid:28555652
    OpenUrlCrossRefPubMed
  4. ↵
    1. Organ Procurement and Transplantation Network
    : Educational guidance on patient referral to kidney transplantation, 2015. Available at: https://optn.transplant.hrsa.gov/resources/guidance/educational-guidance-on-patient-referral-to-kidney-transplantation/. Accessed June 1, 2020
  5. ↵
    1. Organ Procurement and Transplantation Network
    : Organ Procurement Transplantation Network national data report: Current U.S. waiting list, 2019. Available at: https://optn.transplant.hrsa.gov/data/. Accessed June 1, 2020
  6. ↵
    1. Patzer REPL,
    2. Plantinga L,
    3. Krisher J,
    4. Pastan SO
    : Dialysis facility and network factors associated with low kidney transplantation rates among United States dialysis facilities. Am J Transplant 14: 1562–1572, 2014pmid:24891272
    OpenUrlCrossRefPubMed
  7. ↵
    1. Gander JC,
    2. Zhang X,
    3. Ross K,
    4. Wilk AS,
    5. McPherson L,
    6. Browne T,
    7. Pastan SO,
    8. Walker E,
    9. Wang Z,
    10. Patzer RE
    : Association between dialysis facility ownership and access to kidney transplantation. JAMA 322: 957–973, 2019 doi:10.1001/jama.2019.12803 pmid:31503308
    OpenUrlCrossRefPubMed
  8. ↵
    1. Kucirka LM,
    2. Grams ME,
    3. Balhara KS,
    4. Jaar BG,
    5. Segev DL
    : Disparities in provision of transplant information affect access to kidney transplantation. Am J Transplant 12: 351–357, 2012 10.1111/j.1600-6143.2011.03865.xpmid:22151011
    OpenUrlCrossRefPubMed
  9. ↵
    1. Garg PP,
    2. Frick KD,
    3. Diener-West M,
    4. Powe NR
    : Effect of the ownership of dialysis facilities on patients’ survival and referral for transplantation. N Engl J Med 341: 1653–1660, 1999pmid:10572154
    OpenUrlCrossRefPubMed
  10. ↵
    1. Zhang Y,
    2. Thamer M,
    3. Kshirsagar O,
    4. Cotter DJ,
    5. Schlesinger MJ
    : Dialysis chains and placement on the waiting list for a cadaveric kidney transplant. Transplantation 98: 543–551, 2014 doi:10.1097/TP.0000000000000106 pmid:24798304
    OpenUrlCrossRefPubMed
  11. ↵
    1. Patzer RE,
    2. Pastan SO
    : Kidney transplant access in the Southeast: View from the bottom. Am J Transplant 14: 1499–1505, 2014 doi:10.1111/ajt.12748 pmid:24891223
    OpenUrlCrossRefPubMed
  12. ↵
    1. Centers for Medicare & Medicaid Services
    : Dialysis Facility Compare 2018 Handbook. Available at: https://dialysisdata.org/sites/default/files/content/Methodology/Dialysis_Facility_Compare_Handbook.pdf. Accessed June 1, 2020
  13. ↵
    1. Centers for Medicare & Medicaid Services
    : Guide to the dialysis facility reports for fiscal year 2016: Overview, methodology, and interpretation, 2015. Available at: https://dialysisdata.org/sites/default/files/content/dfr_data/FY2016_DFR_Guide.pdf. Accessed June 1, 2020
  14. ↵
    1. Patzer RE,
    2. McPherson L,
    3. Wang Z,
    4. Plantinga LC,
    5. Paul S,
    6. Ellis M,
    7. DuBay DA,
    8. Wolf J,
    9. Reeves-Daniel A,
    10. Jones H,
    11. Zayas C,
    12. Mulloy L,
    13. Pastan SO
    : Dialysis facility referral and start of evaluation for kidney transplantation among patients treated with dialysis in the Southeastern United States. Am J Transplant 20: 2113–2125, 2020 doi:10.1111/ajt.15791 pmid:31981441
    OpenUrlCrossRefPubMed
  15. ↵
    1. Sterne JAC,
    2. White IR,
    3. Carlin JB,
    4. Spratt M,
    5. Royston P,
    6. Kenward MG,
    7. Wood AM,
    8. Carpenter JR
    : Multiple imputation for missing data in epidemiological and clinical research: Potential and pitfalls. BMJ 338: b2393, 2009 doi:10.1136/bmj.b2393 pmid:19564179
    OpenUrlFREE Full Text
  16. ↵
    1. Patzer RE,
    2. Amaral S,
    3. Wasse H,
    4. Volkova N,
    5. Kleinbaum D,
    6. McClellan WM
    : Neighborhood poverty and racial disparities in kidney transplant waitlisting. J Am Soc Nephrol 20: 1333–1340, 2009 doi:10.1681/ASN.2008030335 pmid:19339381
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Waterman AD,
    2. Peipert JD,
    3. Goalby CJ,
    4. Dinkel KM,
    5. Xiao H,
    6. Lentine KL
    : Assessing transplant education practices in dialysis centers: Comparing educator reported and Medicare data. Clin J Am Soc Nephrol 10: 1617–1625, 2015 doi:10.2215/CJN.09851014 pmid:26292696
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Balhara KS,
    2. Kucirka LM,
    3. Jaar BG,
    4. Segev DL
    : Disparities in provision of transplant education by profit status of the dialysis center. Am J Transplant 12: 3104–3110, 2012 10.1111/j.1600-6143.2012.04207.xpmid:22883444
    OpenUrlCrossRefPubMed
  19. ↵
    1. Salter ML,
    2. Orandi B,
    3. McAdams-DeMarco MA,
    4. Law A,
    5. Meoni LA,
    6. Jaar BG,
    7. Sozio SM,
    8. Kao WHL,
    9. Parekh RS,
    10. Segev DL
    : Patient- and provider-reported information about transplantation and subsequent waitlisting. J Am Soc Nephrol 25: 2871–2877, 2014 doi:10.1681/ASN.2013121298 pmid:25168028
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Centers for Medicare & Medicaid Services
    : ESRD quality incentive program, 2021. Available at: https://www.cms.gov/medicare/quality-initiatives-patient-assessment-instruments/esrdqip/. Accessed June 1, 2020
  21. ↵
    1. Paul S,
    2. Plantinga LC,
    3. Pastan SO,
    4. Gander JC,
    5. Mohan S,
    6. Patzer RE
    : Standardized transplantation referral ratio to assess performance of transplant referral among dialysis facilities. Clin J Am Soc Nephrol 13: 282–289, 2018 doi:10.2215/CJN.04690417 pmid:29371341
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Paul S,
    2. Melanson T,
    3. Mohan S,
    4. Ross-Driscoll K,
    5. McPherson L,
    6. Lynch R,
    7. Lo D,
    8. Pastan SO,
    9. Patzer RE
    : Kidney transplant program waitlisting rate as a metric to assess transplant access. Am J Transplant 21: 314–321, 2021 doi:10.1111/ajt.16277 pmid:32808730
    OpenUrlCrossRefPubMed
  23. ↵
    1. IPRO
    : 2018 CMS statement of work for ESRD networks. Available at: https://esrd.ipro.org/wp-content/uploads/2017/11/2017-10-30-Statement-of-Work.pdf. Accessed June 1, 2020
  24. ↵
    1. Hippen BE,
    2. Reed AI,
    3. Ketchersid T,
    4. Maddux FW
    : Implications of the Advancing American Kidney Health Initiative for kidney transplant centers. Am J Transplant 20: 1244–1250, 2020 doi:10.1111/ajt.15619 pmid:31561276
    OpenUrlCrossRefPubMed
  25. ↵
    1. Centers for Medicare & Medicaid Services
    : End-Stage Renal Disease Treatment Choices (ETC) model fact sheet, 2020. Available at: https://www.cms.gov/newsroom/fact-sheets/end-stage-renal-disease-treatment-choices-etc-model-fact-sheet. Accessed February 5, 2021
Back to top

In this issue

View Selected Citations (0)
Print
Download PDF
Email Article
Citation Tools
Request Permissions
Dialysis Facility Profit Status and Early Steps in Kidney Transplantation in the Southeastern United States
Laura J. McPherson, Elizabeth R. Walker, Yi-Ting Hana Lee, Jennifer C. Gander, Zhensheng Wang, Amber M. Reeves-Daniel, Teri Browne, Matthew J. Ellis, Ana P. Rossi, Stephen O. Pastan, Rachel E. Patzer, on behalf of the Southeastern Kidney Transplant Coalition
CJASN Jun 2021, 16 (6) 926-936; DOI: 10.2215/CJN.17691120
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo

Jump to section

Keywords